Q2 25 EPS
$-0.95
MISS 57.02%
Est. $-0.61
Q2 25 Revenue
$110.6M
BEAT +24.54%
Est. $88.8M
vs S&P Since Q2 25
+44.5%
BEATING MARKET
BBIO +60.3% vs S&P +15.9%
Market Reaction
Did BBIO Beat Earnings? Q2 2025 Results
BridgeBio Pharma delivered a split verdict in Q2 2025, posting revenue of $110.56 million that exceeded the $88.78 million consensus by 24.54% while reporting a loss per share of $0.95, wider than the $0.60 consensus estimate by 57.02%. The revenue f… Read more BridgeBio Pharma delivered a split verdict in Q2 2025, posting revenue of $110.56 million that exceeded the $88.78 million consensus by 24.54% while reporting a loss per share of $0.95, wider than the $0.60 consensus estimate by 57.02%. The revenue figure represents a staggering 4,999.9% increase year-over-year, reflecting the company's rapid transformation from clinical-stage to commercial-stage biotech on the back of Attruby, its ATTR-CM therapy, which generated $71.50 million in U.S. Net product revenue, nearly doubling from the prior quarter. The deeper loss, with net losses widening to $181.90 million from $73.46 million a year ago, stems directly from a $69.60 million surge in SG&A expenses tied to the Attruby commercial launch. Analysts have since raised both their revenue and loss estimates for 2025, reflecting the inherent costs of scaling a new commercial operation. Looking ahead, BridgeBio expects Phase 3 topline readouts for BBP-418 and encaleret in fall 2025, catalysts that could meaningfully redefine the company's long-term profile, with management characterizing its $756.89 million cash position as sufficient to fund both the launch and pipeline milestones.
Key Takeaways
- • Accelerating Attruby commercial launch with product revenue nearly doubling quarter-over-quarter
- • Growing adoption across centers of excellence and community physicians with 3,751 unique patient prescriptions by 1,074 unique prescribers
- • Strong month-over-month growth in treatment-naïve patient segment
- • $30 million regulatory milestone from Alexion upon Japan pricing approval of BEYONTTRA
- • New ATTRibute-CM analyses reinforcing Attruby's differentiated clinical profile including 59% relative risk reduction in variant ATTR-CM patients
BBIO YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
BBIO Revenue by Segment
With YoY comparisons, source: SEC Filings
“The launch of Attruby continues to accelerate, increasing the number of patients' lives we are able to touch. We remain grateful for the physicians and patients who are partnering with us on both treatment and on new clinical research.”
— Neil Kumar, Q2 2025 Earnings Press Release
BBIO Earnings Trends
BBIO vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BBIO EPS Trend
Earnings per share: estimate vs actual
BBIO Revenue Trend
Quarterly revenue: estimate vs actual
BBIO Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.62 | $-0.84 | -36.21% | $194.5M | +8.90% |
| Q4 25 MISS FY | $-0.62 | $-1.00 | -60.44% | $154.2M | +3.42% |
| FY Full Year | $-3.19 | $-3.78 | -18.50% | $502.1M | +0.91% |
| Q3 25 MISS | $-0.78 | $-0.95 | -22.31% | $120.7M | +14.23% |
| Q2 25 MISS | $-0.61 | $-0.95 | -57.02% | $110.6M | +24.54% |
| Q1 25 BEAT | $-1.00 | $-0.88 | +11.78% | $116.6M | +102.06% |